tirzepatide august 24 2025 Injection Rotation Map Eli Lilly's tirzepatide gained FDA

In the United States, the FDA shifted from shortage-era flexibility toward enforcement in 2026, including a February 2026 announcement to restrict use of non-FDA-approved GLP-1 active pharmaceutical ingredients in compounded products and an April 2026 clarification of compounding policies under sections 503A and 503B as national supply began stabilizing

This means the DVT signal is most visible for semaglutide simply because there is more data available, not necessarily because it carries a uniquely higher risk

How do GLP-1 meds differ from other weight loss medications

Quick biochemical suppression of dopamine creates an immediate, noticeable effect on desire

Persistent anxiety beyond 14 days warrants stopping the protocol